EnglishУкраїнська
  • Main
  • Useful links
  • Information for Contributors
  • About
  • Editorial board

  • Article
    Filippova O.Yu.

    LIPID METABOLISM FEATURES IN PATIENTS WITH THE COMBINATION OF NON-ALCOHOLIC STEATOHEPATITIS AND ITS CORRECTION


    About the author: Filippova O.Yu.
    Heading CLINICAL MEDICINE
    Type of article Scentific article
    Annotation The purpose of the study was to estimate the effects of different treatment regimens on lipid metabolism in patients with non-alcoholic steatohepatitis (NASH) in combination with obesity (OB) and pathology of the biliary tract (BT) according to the 6-month dynamic observation. A dynamic study of 100 patients with NASH in combination with OB and BT pathology was performed, including the lipid metabolism indices study. It was found that lipid metabolism disorders occurred in all groups of patients, being characterized by an increase in triglycerides, cholesterol of low density lipoproteins, and disorders of metabolism and transport of the total cholesterol and reduced cholesterol levels of high density lipoproteins in comparison with apparently healthy individuals (from p <0.05 to p < 0.001). Combined therapy including ursodeoxycholic acid and arginine glutamate in addition to the standard treatment at the comorbid NASH course can be considered as a promising treatment direction in this category of patients, which permits to achieve the restoration of the main lipid metabolism indices (from p <0.05 to p <0.001).
    Tags nonalcoholic steatohepatitis, obesity, lipid metabolism, ursodeoxycholic acid, arginine glutamate
    Bibliography
    • Babak OYa, Fadieyenko HD, Frolov VM, Kruhlova OV. Patohenetychne obgruntuvannya vykorystannya metabolichno aktyvnoho zasoby L-arhininu-L-hlutamat pry nealkoholniy zhiroviy khvorobi pechinky, poyednaniy z khronichnim nekalkulyoznym kholetsystytom. Liky Ukrayiny. 2013; 2:129–133. [in Ukrainian]
    • Hrechanyk MM. Kardiohemodynamika ta pokaznyky pruzhno-elastychnykh vlastyvostey karotydnykh arteriy u khvorykh z ishemichnoyu khvoroboyu sertsya v poyednanni z nealkoholnym steatozom pechinky. Aktualni problemy suchasnoyi medytsyny: Visnyk Ukrayinskoyi medychnoyi stomatolohichnoyi akademiyi. 2017; 3:101–105. [in Ukrainian]
    • Kuryata AV, Hrechanyk MM. Ateroskleroz mahistralnykh arteriy holovy, riven leptynu ta postprandialna hypertryhlytserydemyya u patsiyentiv z ishemichnoyu khvoroboyu sertsya v poyednanni z nealkoholnoyu zhyrovoyu khvoroboyu pechinky v zalezhnosti vid indeksu masy tila. Ukrayinskyi terapevtychnyi zhurnal. 2016; 4:55–62. [in Ukrainian]
    • Skrypnyk IM, Maslova HS, Shcherbak OV. Vplyv hipolipidemichnoyi terapiyi na stan systemy oksydu azotu u khvoroho na ishemichnu khvorobu sertsya v poyednanni z nealkoholnym steatohepatytom. Svit medytsyny ta biolohiyi. 2017; 4: 93–99. [in Ukrainian]
    • Stepanov YuM, Filippova OYu. Vplyv masy tila ta suputnioyi patolohiyi biliarnoho traktu na rozvytok y prohresuvannya lipidnykh porushen yak u khvorykh na nealkoholnu zhyrovu khvorobu pechinki u poyednanni z ozhirinnyam. Suchasna hastroenterolohiya. 2016; 4:7–15. [in Ukrainian]
    • Filippova OYu. Lipidno-fosfolipidni porushennya u patsiyentiv z komorbidnym perebihom nealkoholnoyi zhyrovoyi khvoroby pechinky ta ozhyrinnyam na tli patolohiyi biliarnoho traktu zalezhno vid masy tila. Svit medytsyny ta biolohiyi. 2016; 3:85–90. [in Ukrainian]
    • Abd El-Kader SM, El-Den Ashmawy EM. Non-alcoholic fatty liver disease: The diagnosis and management. World J. Hepatol. 2015; 6:846–858.
    • Bril F, Sninsky JJ, Baca AM,  Superko HR, Portillo Sanchez P, Biernacki D et al. Hepatic steatosis and insulinresistance, but not steatohepatitis, promote atherogenic dyslipidemia in NAFLD. J. Clin. Endocrinol. Metab. 2016; 101: 644–652.
    • Fotbolcu  H, Zorlu E. Nonalcoholic fatty liver disease as a multi-systemic disease. World J Gastroenterol. 2016; 16:4079-4090.
    • Katsiki N, Mikhailidis DP, Mantzoros CS. Non-alcoholic fatty liver disease and dyslipidemia: An update. Metabolism. 2016; 8:1109–1123.
    • Nseir W, Hellou E, Assy N. Role of diet and lifestyle changes in nonalcoholic fatty liver disease . World J. Gastroenterol. 2014; 28:9338–9344.
    • Pallayova M, Taheri S. Non-alcoholic fatty liver disease in obese adults: clinical aspects and current management strategies. Clin. Obes. 2014; 5:243–253.
    • Shephard  RJ, Johnson  N. Effects of physical activity upon the liver. Eur. J. Appl. Physiol. 2015; 115:1–46.
    • Shi FY, Gao WF, Tao EX, Liu HQ, Wang SZ. Metabolic syndrome is a risk factor for nonalcoholic fatty liver disease: evidence from a confirmatory factor analysis and structural equation modeling. Eur. Rev. Med. Pharmacol. Sci. 2016; 20: 4313–4321.
    • Takahashi Y, Sugimoto K,  Inui H, Fukusato T. Current pharmacological therapies for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. World J. Gastroenterol. 2015; 13:3777–3785.
    Publication of the article «World of Medicine and Biology» №4(70), 2019 year, 172-177 pages, index UDK 616.36-003.826-06-085:612.97
    DOI 10.26724/2079-8334-2019-4-70-172-177